60 related articles for article (PubMed ID: 32666385)
21. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
[TBL] [Abstract][Full Text] [Related]
22. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
23. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
25. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
[TBL] [Abstract][Full Text] [Related]
26. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.
Shi Y; Gong W; Lu L; Wang Y; Ren J
Braz J Med Biol Res; 2019; 52(11):e8657. PubMed ID: 31664305
[TBL] [Abstract][Full Text] [Related]
28. HMGB1-Induced p62 Overexpression Promotes Snail-Mediated Epithelial-Mesenchymal Transition in Glioblastoma Cells via the Degradation of GSK-3β.
Li H; Li J; Zhang G; Da Q; Chen L; Yu S; Zhou Q; Weng Z; Xin Z; Shi L; Ma L; Huang A; Qi S; Lu Y
Theranostics; 2019; 9(7):1909-1922. PubMed ID: 31037147
[No Abstract] [Full Text] [Related]
29. Glycyrrhizin Attenuates the Process of Epithelial-to-Mesenchymal Transition by Modulating HMGB1 Initiated Novel Signaling Pathway in Prostate Cancer Cells.
Chang HY; Chen SY; Wu CH; Lu CC; Yen GC
J Agric Food Chem; 2019 Mar; 67(12):3323-3332. PubMed ID: 30832473
[TBL] [Abstract][Full Text] [Related]
30. The progression of HMGB1-induced autophagy in cancer biology.
Xu T; Jiang L; Wang Z
Onco Targets Ther; 2019; 12():365-377. PubMed ID: 30643434
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib.
Garbe C; Eigentler TK
Recent Results Cancer Res; 2018; 211():77-89. PubMed ID: 30069761
[TBL] [Abstract][Full Text] [Related]
32. HMGB1-mediated autophagy confers resistance to gemcitabine in hormone-independent prostate cancer cells.
Zhang YX; Yuan YQ; Zhang XQ; Huang DL; Wei YY; Yang JG
Oncol Lett; 2017 Nov; 14(5):6285-6290. PubMed ID: 29113279
[TBL] [Abstract][Full Text] [Related]
33. Autophagy and multidrug resistance in cancer.
Li YJ; Lei YH; Yao N; Wang CR; Hu N; Ye WC; Zhang DM; Chen ZS
Chin J Cancer; 2017 Jun; 36(1):52. PubMed ID: 28646911
[TBL] [Abstract][Full Text] [Related]
34. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.
Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
[TBL] [Abstract][Full Text] [Related]
35. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Lim H; Devesa SS; Sosa JA; Check D; Kitahara CM
JAMA; 2017 Apr; 317(13):1338-1348. PubMed ID: 28362912
[TBL] [Abstract][Full Text] [Related]
36. Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma.
Guan X; Wang P; Chi J; Zhao S; Wang F
Biochem Biophys Res Commun; 2017 May; 486(4):898-903. PubMed ID: 28342873
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
38. A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer.
Takacsova E; Kralik R; Waczulikova I; Zavodna K; Kausitz J
Neoplasma; 2017; 64(1):156-164. PubMed ID: 27881018
[TBL] [Abstract][Full Text] [Related]
39. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
40. Recent insights into the function of autophagy in cancer.
Amaravadi R; Kimmelman AC; White E
Genes Dev; 2016 Sep; 30(17):1913-30. PubMed ID: 27664235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
